Details

Autor(en) / Beteiligte

• OLIVOTTO, Ivo A
• BAJDIK, Chris D
• RAVDIN, Peter M
• SPEERS, Caroline H
• COLDMAN, Andrew J
• NORRIS, Brian D
• DAVIS, Greg J
• CHIA, Stephen K
• GELMON, Karen A

Titel

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Ist Teil von

• Journal of clinical oncology, 2005-04, Vol.23 (12), p.2716-2725

Ort / Verlag

Baltimore, MD: American Society of Clinical Oncology

Erscheinungsjahr

2005

Quelle

MEDLINE

Beschreibungen/Notizen

• Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer-specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted-observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted-observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.